Professor Judith Trotman is a Senior Staff Specialist and Director of the Clinical Research Unit in the Haematology Department, Concord Repatriation General Hospital, Sydney, AU. She has particular expertise in the management of lymphoid malignancies.
Prof. Trotman and colleagues have built one of the largest clinical research units in Australia for collaboration in a broad portfolio of hematological trials. She is a member of the Australasian Leukaemia and Lymphoma Group ( ALLG) Scientific Advisory Committee and Chair of the Low-Grade Lymphoma Committee. She is the ALLG Principal Investigator for several national trials and international lymphoma collaborations with French (PRIMA, REMARC), Italian (FOLLCOLL), and UK lymphoma cooperative groups, including the RATHL trial - Response Adapted Therapy in Hodgkin lymphoma — a study delivering PET-adapted therapy to patients with advanced Hodgkin lymphoma. She is a co-author of the International Imaging Guidelines in staging and response assessment of lymphoma and leads an international collaboration demonstrating the predictive power of both baseline and end-of-treatment PET in follicular lymphoma. She is currently trialing a PET-adapted approach in relapsed follicular lymphoma. Beyond lymphoma, she leads a study designed to optimize dosing of melphalan in myeloma transplantation. In this modern digital era, she is committed to facilitating cross-center collaboration in trial recruitment across the broad spectrum of rare hematological malignancies. She is the co-inventor of ClinTrial Refer — a non-profit, free-to-download application that has increased patient cross-referrals across numerous international cancer trial portfolios.